Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy could result in adverse perinatal outcome. Clinical data on the assessment of the immune response in vaccinated pregnant women and subsequent transplacental antibody transfer are quite limited. Object...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/1/101 |
| _version_ | 1797489895755743232 |
|---|---|
| author | Ching-Ju Shen Yi-Chen Fu Yen-Pin Lin Ching-Fen Shen Der-Ji Sun Huan-Yun Chen Chao-Min Cheng |
| author_facet | Ching-Ju Shen Yi-Chen Fu Yen-Pin Lin Ching-Fen Shen Der-Ji Sun Huan-Yun Chen Chao-Min Cheng |
| author_sort | Ching-Ju Shen |
| collection | DOAJ |
| description | Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy could result in adverse perinatal outcome. Clinical data on the assessment of the immune response in vaccinated pregnant women and subsequent transplacental antibody transfer are quite limited. Objective: To assess maternal and neonatal neutralizing antibody levels against both wildtype and Delta (B.1.617.2) variants after maternal mRNA vaccination. Study Design: This cohort study was conducted 29 pregnant women who were vaccinated at least one dose of Moderna (mRNA-1273) vaccine. Both neutralizing antibody (wildtype and Delta variant) and S1 receptor binding domain IgG antibody levels were evaluated in maternal and cord blood on the day of delivery. Results: Superiority of antibody level was significant in fully vaccinated women compared with the one-dose group (maternal sera, median, 97.46%; cord sera, median, 97.37% versus maternal sera, median, 4.01%; cord sera, median, 1.44%). No difference in antibody level was noted in relation to interval of second immunization to delivery in the two-dose group (95.99% in 0–2 weeks, 97.45% in 2–4 weeks, 97.48% in 4–8 weeks, 97.72% in 8–10 weeks). The most pronounced reduction was observed for the Delta variant. The wildtype neutralizing antibody level of full-vaccinated women was not influenced by the pertussis vaccination. Conclusion: The data underscore the importance of full vaccination in pregnancy and support the recommendation of COVID-19 immunization for pregnant women. The lower level of vaccine-induced neutralizing antibodies for the Delta variant indicates insufficient protection for mother and newborn and highlights the need for development of effective vaccine strategies. |
| first_indexed | 2024-03-10T00:23:10Z |
| format | Article |
| id | doaj.art-cf47ccf2db2648d9bcc83cbb3adc867a |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T00:23:10Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-cf47ccf2db2648d9bcc83cbb3adc867a2023-11-23T15:39:27ZengMDPI AGVaccines2076-393X2022-01-0110110110.3390/vaccines10010101Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant WomenChing-Ju Shen0Yi-Chen Fu1Yen-Pin Lin2Ching-Fen Shen3Der-Ji Sun4Huan-Yun Chen5Chao-Min Cheng6Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, TaiwanInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, TaiwanInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, TaiwanDepartment of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDepartment of Obstetrics and Gynecology, Pojen Hospital, Kaohsiung 804, TaiwanDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, TaiwanInstitute of Biomedical Engineering, National Tsing Hua University, Hsinchu 300, TaiwanBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy could result in adverse perinatal outcome. Clinical data on the assessment of the immune response in vaccinated pregnant women and subsequent transplacental antibody transfer are quite limited. Objective: To assess maternal and neonatal neutralizing antibody levels against both wildtype and Delta (B.1.617.2) variants after maternal mRNA vaccination. Study Design: This cohort study was conducted 29 pregnant women who were vaccinated at least one dose of Moderna (mRNA-1273) vaccine. Both neutralizing antibody (wildtype and Delta variant) and S1 receptor binding domain IgG antibody levels were evaluated in maternal and cord blood on the day of delivery. Results: Superiority of antibody level was significant in fully vaccinated women compared with the one-dose group (maternal sera, median, 97.46%; cord sera, median, 97.37% versus maternal sera, median, 4.01%; cord sera, median, 1.44%). No difference in antibody level was noted in relation to interval of second immunization to delivery in the two-dose group (95.99% in 0–2 weeks, 97.45% in 2–4 weeks, 97.48% in 4–8 weeks, 97.72% in 8–10 weeks). The most pronounced reduction was observed for the Delta variant. The wildtype neutralizing antibody level of full-vaccinated women was not influenced by the pertussis vaccination. Conclusion: The data underscore the importance of full vaccination in pregnancy and support the recommendation of COVID-19 immunization for pregnant women. The lower level of vaccine-induced neutralizing antibodies for the Delta variant indicates insufficient protection for mother and newborn and highlights the need for development of effective vaccine strategies.https://www.mdpi.com/2076-393X/10/1/101neutralizing antibodyCOVID-19 vaccinepregnancycord bloodDelta variantmaternal immunity |
| spellingShingle | Ching-Ju Shen Yi-Chen Fu Yen-Pin Lin Ching-Fen Shen Der-Ji Sun Huan-Yun Chen Chao-Min Cheng Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women Vaccines neutralizing antibody COVID-19 vaccine pregnancy cord blood Delta variant maternal immunity |
| title | Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women |
| title_full | Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women |
| title_fullStr | Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women |
| title_full_unstemmed | Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women |
| title_short | Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women |
| title_sort | evaluation of transplacental antibody transfer in sars cov 2 immunized pregnant women |
| topic | neutralizing antibody COVID-19 vaccine pregnancy cord blood Delta variant maternal immunity |
| url | https://www.mdpi.com/2076-393X/10/1/101 |
| work_keys_str_mv | AT chingjushen evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen AT yichenfu evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen AT yenpinlin evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen AT chingfenshen evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen AT derjisun evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen AT huanyunchen evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen AT chaomincheng evaluationoftransplacentalantibodytransferinsarscov2immunizedpregnantwomen |